Ticagrelor Tablet, Film Coated
Product Images NDC 43547-657

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 43547-657). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C7aeae20-figure-01 (C7aeae20 Figure 01)

A cumulative percentage line graph comparing two groups receiving Ticagrelor 90 mg and Clopidogrel over 360 days from the first study drug dose. The x-axis shows days, and the y-axis shows cumulative percentage. The chart includes event counts, patient numbers at risk, and Kaplan-Meier percentages at 12 months for each group.*

FDA Label Image

C7aeae20-figure-02 (C7aeae20 Figure 02)

A bar chart showing the percentage of patients who had an event following coronary artery bypass graft (CABG) surgery over 8 or more days. The x-axis represents days, with data for days 1 through 8+. Two groups are compared, labeled T and C, with corresponding event percentages on the y-axis ranging from 0 to 100 percent.*

FDA Label Image

C:\users\ra\desktop\untitled.jpg (C7aeae20 Figure 03)

Chemical structure of ticagrelor, the active ingredient in TICAGRELOR 90 mg oral film-coated tablets by Solco Healthcare U.S., LLC. The structure shows the molecular framework including rings, hydroxyl groups, and fluorinated aromatic components.*

FDA Label Image

C7aeae20-figure-05 (C7aeae20 Figure 04)

A line graph depicting platelet inhibition activity (IPA %) over time (hours) induced by 20uM ADP. It compares the effects of Ticagrelor 180 mg, Clopidogrel 600 mg, and a placebo from 0 to 8 hours. Ticagrelor shows a rapid and sustained high IPA, Clopidogrel shows moderate IPA increasing over time, and placebo shows minimal IPA.*

FDA Label Image

C7aeae20-figure-06 (C7aeae20 Figure 05)

A line graph comparing IPA (%) induced by 20µM ADP over time (days) for Ticagrelor, Clopidogrel, and Placebo. Ticagrelor shows the highest initial IPA response, followed by Clopidogrel, with Placebo near zero. An inset graph displays IPA (%) over hours, showing a similar trend within the first 48 hours.*

FDA Label Image

Figure7 (C7aeae20 Figure 06)

A comparative plot showing mean effect and 90% confidence intervals for ticagrelor pharmacokinetics (Cmax and AUC) across intrinsic factors like age, gender, ethnicity, renal and hepatic impairment. It includes reference comparisons for ticagrelor and AR-C124910XX, with no dose adjustments recommended for any factors.*

FDA Label Image

Figure-08 (C7aeae20 Figure 07)

A figure showing the mean effect with 90% confidence intervals of various interacting drugs on ticagrelor and AR-C124910XX, measured by changes in Cmax and AUC relative to reference. The chart lists drugs including strong and moderate CYP3A4 inhibitors, CYP3A4 inducers, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, along with dosing information and recommendations such as avoiding concomitant use or no dose adjustment needed.*

FDA Label Image

C7aeae20-figure-09 (C7aeae20 Figure 08)

A pharmacokinetic chart illustrating the interaction effects of various drugs with different doses of ticagrelor. The graph plots mean effect with 90% confidence intervals showing changes in Cmax and AUC relative to ticagrelor alone. Drugs assessed include simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine, accompanied by dosing and recommendation notes for dose adjustments.*

FDA Label Image

C7aeae20-figure-10 (C7aeae20 Figure 09)

A Kaplan-Meier survival curve chart comparing the cumulative percentages of patients experiencing events over days from randomization for Ticagrelor 90 mg tablets versus Clopidogrel. The x-axis represents days from randomization up to 360 days, and the y-axis shows cumulative percentage of events. The chart includes a legend and a table of patient numbers at risk over time.*

FDA Label Image

C7aeae20-figure-11 (C7aeae20 Figure 10)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals (CI) for ticagrelor versus clopidogrel across various patient subgroups and treatment characteristics. The variables include overall treatment effect, geographic region, aspirin dose, treatment approach, medical history, age, sex, and race. The chart visually represents whether ticagrelor or clopidogrel shows better outcomes in each subgroup.*

FDA Label Image

C7aeae20-figure-12 (C7aeae20 Figure 11)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals for ticagrelor versus clopidogrel across US and non-US regions and different aspirin dose categories. The chart illustrates data points with corresponding confidence intervals, showing variation in HR values by region and aspirin dose.*

FDA Label Image

Figure 13 (C7aeae20 Figure 12)

A cumulative incidence plot comparing ticagrelor 90 mg and placebo over days from randomization. It shows the percentage of patients with events on the y-axis and time in days on the x-axis, with lines for ticagrelor and placebo groups and a table of numbers at risk below the graph.*

FDA Label Image

90 mg 60 Ct (C7aeae20 Figure 14)

The packaging label for Ticagrelor Tablets 90 mg film-coated tablets. The label indicates a package size of 60 tablets, distributed by Solco Healthcare US, LLC. The label includes storage instructions, a medication guide link, and manufacturing details from Zhejiang Huahai Pharmaceutical Co., Ltd. The design features a blue and green color scheme with the Solco logo.*

FDA Label Image

Figure4 (Image 02)

A Kaplan-Meier curve chart comparing cumulative percentage over days from randomization between Ticagrelor 90 mg tablet and placebo groups. The solid line represents Ticagrelor 90 mg bd with event data, while the dashed line represents placebo, showing lower cumulative percentage of events over approximately 30 days.*

FDA Label Image

Figure17 (Image 05)

A Kaplan-Meier cumulative incidence curve comparing ticagrelor 90 mg tablet versus placebo over time in days from randomization. The solid line represents ticagrelor and the dashed line placebo, with cumulative percentages shown on the y-axis and days on the x-axis. Risk set counts are displayed below the x-axis.*

FDA Label Image

Figure 18 (Image 06)

A forest plot comparing Ticagrelor 90 mg and placebo across various patient characteristics, showing hazard ratios (HR) with 95% confidence intervals for each subgroup. Characteristics include age, sex, race, weight, BMI, geographic region, diagnosis, NIHSS score, time from index event, diabetes status, hypertension, prior stroke, heart disease, and treatment details. The plot visually contrasts outcomes favoring Ticagrelor versus placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.